Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism

M Spangaro, M Bosia, Margherita Bechi, M Buonocore, F Cocchi, Carmelo Guglielmino, L Bianchi, A Mastromatteo, C Lorenzi, R Cavallaro

Research output: Contribution to journalArticle

Abstract

Cognitive deficits represent core features of schizophrenia, affecting quality of life and functioning. The excitatory amino acid transporter 2 (EAAT2) is responsible for the majority of glutamate reuptake and its activity is crucial for glutamatergic neurotransmission, prevention of excitotoxic damage and cerebral metabolism. Different studies reported that EAAT2 rs4354668 (−181 T/G) influences cognitive functions and brain structures in patients with schizophrenia. Specifically, the G allele, linked to lower EAAT2 expression, was associated with impaired prefrontal cognitive performance and reduced grey matter volumes. Cognitive remediation therapy (CRT) is one of the best available tool to treat cognitive deficits in schizophrenia, able to induce a neuroplastic modulation of cognitive functions. The present study aims to investigate the effects of rs4354668 on CRT outcome, also considering possible genotype interaction with antipsychotic (AP) treatment, since EAAT2 expression is negatively influenced by clozapine. We examined rs4354668 in 88 clinically stabilized patients with schizophrenia, treated with CRT and assessed at enrolment, at the end of CRT and after 3 months. We observed greater working memory improvements among patients carrying the T/T genotype, regardless of AP treatment. Moreover, we reported a significant interaction between pharmacological treatment and rs4354668 on executive functions, with greater improvements among T/T patients treated with APs other than clozapine. These observations suggest that impaired EAAT2 expression may attenuate CRT outcome. Moreover, our results indicate the possibility that rs4354668 could also differentially influence the response to CRT depending on the AP treatment. © 2018 Elsevier B.V.
Original languageEnglish
Pages (from-to)106-110
Number of pages5
JournalSchizophrenia Research
Volume202
DOIs
Publication statusPublished - 2018

Fingerprint

Excitatory Amino Acid Transporter 2
Neurobiology
Cognitive Therapy
Schizophrenia
Antipsychotic Agents
Clozapine
Cognition
Genotype
Executive Function
Therapeutics
Short-Term Memory
Synaptic Transmission
Cognitive Remediation
Glutamic Acid
Alleles
Quality of Life
Pharmacology
Brain

Cite this

Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism. / Spangaro, M; Bosia, M; Bechi, Margherita; Buonocore, M; Cocchi, F; Guglielmino, Carmelo; Bianchi, L; Mastromatteo, A; Lorenzi, C; Cavallaro, R.

In: Schizophrenia Research, Vol. 202, 2018, p. 106-110.

Research output: Contribution to journalArticle

Spangaro, M, Bosia, M, Bechi, M, Buonocore, M, Cocchi, F, Guglielmino, C, Bianchi, L, Mastromatteo, A, Lorenzi, C & Cavallaro, R 2018, 'Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism', Schizophrenia Research, vol. 202, pp. 106-110. https://doi.org/10.1016/j.schres.2018.06.059
Spangaro, M ; Bosia, M ; Bechi, Margherita ; Buonocore, M ; Cocchi, F ; Guglielmino, Carmelo ; Bianchi, L ; Mastromatteo, A ; Lorenzi, C ; Cavallaro, R. / Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism. In: Schizophrenia Research. 2018 ; Vol. 202. pp. 106-110.
@article{280f6e78e1e1458f9f66e1ebe8c298a1,
title = "Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism",
abstract = "Cognitive deficits represent core features of schizophrenia, affecting quality of life and functioning. The excitatory amino acid transporter 2 (EAAT2) is responsible for the majority of glutamate reuptake and its activity is crucial for glutamatergic neurotransmission, prevention of excitotoxic damage and cerebral metabolism. Different studies reported that EAAT2 rs4354668 (−181 T/G) influences cognitive functions and brain structures in patients with schizophrenia. Specifically, the G allele, linked to lower EAAT2 expression, was associated with impaired prefrontal cognitive performance and reduced grey matter volumes. Cognitive remediation therapy (CRT) is one of the best available tool to treat cognitive deficits in schizophrenia, able to induce a neuroplastic modulation of cognitive functions. The present study aims to investigate the effects of rs4354668 on CRT outcome, also considering possible genotype interaction with antipsychotic (AP) treatment, since EAAT2 expression is negatively influenced by clozapine. We examined rs4354668 in 88 clinically stabilized patients with schizophrenia, treated with CRT and assessed at enrolment, at the end of CRT and after 3 months. We observed greater working memory improvements among patients carrying the T/T genotype, regardless of AP treatment. Moreover, we reported a significant interaction between pharmacological treatment and rs4354668 on executive functions, with greater improvements among T/T patients treated with APs other than clozapine. These observations suggest that impaired EAAT2 expression may attenuate CRT outcome. Moreover, our results indicate the possibility that rs4354668 could also differentially influence the response to CRT depending on the AP treatment. {\circledC} 2018 Elsevier B.V.",
author = "M Spangaro and M Bosia and Margherita Bechi and M Buonocore and F Cocchi and Carmelo Guglielmino and L Bianchi and A Mastromatteo and C Lorenzi and R Cavallaro",
year = "2018",
doi = "10.1016/j.schres.2018.06.059",
language = "English",
volume = "202",
pages = "106--110",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism

AU - Spangaro, M

AU - Bosia, M

AU - Bechi, Margherita

AU - Buonocore, M

AU - Cocchi, F

AU - Guglielmino, Carmelo

AU - Bianchi, L

AU - Mastromatteo, A

AU - Lorenzi, C

AU - Cavallaro, R

PY - 2018

Y1 - 2018

N2 - Cognitive deficits represent core features of schizophrenia, affecting quality of life and functioning. The excitatory amino acid transporter 2 (EAAT2) is responsible for the majority of glutamate reuptake and its activity is crucial for glutamatergic neurotransmission, prevention of excitotoxic damage and cerebral metabolism. Different studies reported that EAAT2 rs4354668 (−181 T/G) influences cognitive functions and brain structures in patients with schizophrenia. Specifically, the G allele, linked to lower EAAT2 expression, was associated with impaired prefrontal cognitive performance and reduced grey matter volumes. Cognitive remediation therapy (CRT) is one of the best available tool to treat cognitive deficits in schizophrenia, able to induce a neuroplastic modulation of cognitive functions. The present study aims to investigate the effects of rs4354668 on CRT outcome, also considering possible genotype interaction with antipsychotic (AP) treatment, since EAAT2 expression is negatively influenced by clozapine. We examined rs4354668 in 88 clinically stabilized patients with schizophrenia, treated with CRT and assessed at enrolment, at the end of CRT and after 3 months. We observed greater working memory improvements among patients carrying the T/T genotype, regardless of AP treatment. Moreover, we reported a significant interaction between pharmacological treatment and rs4354668 on executive functions, with greater improvements among T/T patients treated with APs other than clozapine. These observations suggest that impaired EAAT2 expression may attenuate CRT outcome. Moreover, our results indicate the possibility that rs4354668 could also differentially influence the response to CRT depending on the AP treatment. © 2018 Elsevier B.V.

AB - Cognitive deficits represent core features of schizophrenia, affecting quality of life and functioning. The excitatory amino acid transporter 2 (EAAT2) is responsible for the majority of glutamate reuptake and its activity is crucial for glutamatergic neurotransmission, prevention of excitotoxic damage and cerebral metabolism. Different studies reported that EAAT2 rs4354668 (−181 T/G) influences cognitive functions and brain structures in patients with schizophrenia. Specifically, the G allele, linked to lower EAAT2 expression, was associated with impaired prefrontal cognitive performance and reduced grey matter volumes. Cognitive remediation therapy (CRT) is one of the best available tool to treat cognitive deficits in schizophrenia, able to induce a neuroplastic modulation of cognitive functions. The present study aims to investigate the effects of rs4354668 on CRT outcome, also considering possible genotype interaction with antipsychotic (AP) treatment, since EAAT2 expression is negatively influenced by clozapine. We examined rs4354668 in 88 clinically stabilized patients with schizophrenia, treated with CRT and assessed at enrolment, at the end of CRT and after 3 months. We observed greater working memory improvements among patients carrying the T/T genotype, regardless of AP treatment. Moreover, we reported a significant interaction between pharmacological treatment and rs4354668 on executive functions, with greater improvements among T/T patients treated with APs other than clozapine. These observations suggest that impaired EAAT2 expression may attenuate CRT outcome. Moreover, our results indicate the possibility that rs4354668 could also differentially influence the response to CRT depending on the AP treatment. © 2018 Elsevier B.V.

U2 - 10.1016/j.schres.2018.06.059

DO - 10.1016/j.schres.2018.06.059

M3 - Article

VL - 202

SP - 106

EP - 110

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

ER -